



ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics

ESPS manuscript NO: 21345

Title: Dendritic cell-based vaccine for pancreatic cancer in Japan

Reviewer’s code: 00504169

Reviewer’s country: Italy

Science editor: Fang-Fang Ji

Date sent for review: 2015-07-13 17:28

Date reviewed: 2015-07-20 19:06

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

In this review Okamoto et al illustrate the advantages of a DC vaccine named “Vaccell” which has been established in Japan and optimized by the authors with the use of the streptococcal adjuvant OK-432. It is an important issue and I think of interest for the readers. However, in my opinion a more exhaustive description of the issue is needed. In particular few tables should be added to describe : - Patients characteristics - Immunological assessment of patients enrolled in retrospective and prospective studies as: frequency of CD4 , CD8 and NK cells before and after treatment, analysis by tetramer of antigen-specific Tcells, IFN-gamma and DTH values , cytokines produced by antigen specific T cells, phenotype of PBL subsets i.e neutrophils and/or MDSCs. (In the case of the prospective studies data on WT1-I and /or WT1-II should be reported). - Data on tolerability and side effects.